Business
CareDx Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results
BRISBANE, Calif., January 12, 2026--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high‑value healthcare solutions for transplant patients and caregivers, today reported preliminary, unaudited financial results for the fourth quarter and full year 2025.
About this update from Caredx, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":3066,"height":1021,"url":"https://media.zenfs.com/en/business-wire.com/8bfa36316bd4fd31e967a323338b5bb2"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/SOGNFNLgnLF6CkmmMns5Qg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTMyMDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/8bfa36316bd4fd31e967a323338b5bb2","width":960,"height":320},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/ui7eS.8DxTGQnDSeE6s5bQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD04MDA7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/8bfa36316bd4fd31e967a323338b5bb2","width":1200,"height":400}},"lazy":false},{"type":"text","content":"Expects Fourth Quarter Revenue Growth of Approximately 25% Year-Over-Year","length":73,"tagName":"p","attribs":{}},{"type":"text","content":"Expects Full Year 2025 Revenue of Approximately $380 Million","length":60,"tagName":"p","attribs":{}},{"type":"text","content":"BRISBANE, Calif., January 12, 2026--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high‑value healthcare solutions for transplant patients and caregivers, today reported preliminary, unaudited financial results for the fourth quarter and full year 2025.","length":406,"tagName":"p"},{"type":"text","content":"Preliminary Fourth Quarter 2025 Financial Results","length":49,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Revenue of approximately $108 million, an increase of 25% year-over-year","length":72,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Testing services revenue of approximately $78 million, an increase of 23% year-over-year","length":88,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Testing services volume of approximately 53,000, an increase of 17% year-over-year","length":82,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Average revenue per test of approximately $1,470 including approximately $5 million in prior period revenue","length":107,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Patient & digital solutions revenue of approximately $17 million, an increase of 47% year-ov...